Lending support to the present data, a prior study had shown that the dual FAAH/monoacylglyceride lipase (MGL) inhibitor, which simultaneously blocks the degradation of AEA and 2-AG, lowers serum levels of CGRP in the same animal model of migraine [39]. Here, FAAH is linked to migraine disorder.